Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -12.87% is 77% above its 5-year average of -56.82%, near the high end of its 5-year range (-1718.82%–10.88%).
31.64% above its 12-month average of -18.83%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2027 (2026-06-30): -14.88%.
EBITDA MARGIN
-12.87%
EBITDA MARGIN AVG TTM
-18.83%
EBITDA MARGIN AVG 3Y
-23.98%
EBITDA MARGIN AVG 5Y
-56.82%
EBITDA MARGIN AVG 10Y
-96.28%
EBITDA MARGIN AVG 15Y
-206.78%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+31.64%
CURRENT VS 3Y AVG
+46.32%
CURRENT VS 5Y AVG
+77.35%
CURRENT VS 10Y AVG
+86.63%
CURRENT VS 15Y AVG
+93.78%
CURRENT VS 20Y AVG
N/A
Canopy Growth Corporation
Market Cap
$373.40M
EBITDA Margin
-12.87%
TTM Avg
-18.83%
3Y Avg
-23.98%
5Y Avg
-56.82%
Market Cap
$368.91M
EBITDA Margin
-13.98%
TTM Avg
-3.54%
3Y Avg
-384.69%
5Y Avg
-2364.58%
Market Cap
$366.39M
EBITDA Margin
-122.86%
TTM Avg
-149.66%
3Y Avg
-152.47%
5Y Avg
-125.05%
Market Cap
$348.59M
EBITDA Margin
-25837.05%
TTM Avg
-12960.93%
3Y Avg
-7440.06%
5Y Avg
-7440.06%
Market Cap
$345.48M
EBITDA Margin
-59.31%
TTM Avg
-58.08%
3Y Avg
-69.87%
5Y Avg
-66.91%
Market Cap
$406.47M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canopy Growth Corporation (CGC) | $373.40M | -12.87% | -18.83% | -23.98% | -56.82% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $368.91M | -13.98% | -3.54% | -384.69% | -2364.58% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -122.86% | -149.66% | -152.47% | -125.05% |
| Agenus Inc. (AGEN)vs › | $363.54M | -9.24% | -56.39% | -95.53% | -82.66% |
| Embecta Corp. (EMBC)vs › | $348.85M | 35.21% | 27.25% | 28.55% | 34.67% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -25837.05% | -12960.93% | -7440.06% | -7440.06% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | -59.31% | -58.08% | -69.87% | -66.91% |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | -48.80% | -44.09% | -45.35% | -45.35% |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | N/A | N/A | N/A | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | N/A | N/A | N/A | N/A |
Gross Margin
25.5%
EBITDA Margin
-12.9%
Operating Margin
-32.0%
Net Margin
-81.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -14.88% |
| 2026-03-31 | -26.42% |
| 2025-12-31 | -23.40% |
| 2025-09-30 | -11.47% |
| 2025-06-30 | -17.96% |
| 2025-03-31 | 10.88% |
| 2024-12-31 | -18.07% |
| 2024-09-30 | -56.57% |
| 2024-06-30 | -27.30% |
| 2024-03-31 | -131.13% |
| 2023-12-31 | -61.24% |
| 2023-09-30 | 7.94% |
| 2023-06-30 | -49.23% |
| 2023-03-31 | -894.94% |
| 2022-12-31 | -110.06% |
| 2022-09-30 | -147.37% |
| 2022-06-30 | -1718.82% |
| 2022-03-31 | -446.59% |
| 2021-12-31 | -85.08% |
| 2021-09-30 | -142.02% |
| 2021-06-30 | -119.36% |
| 2021-03-31 | -137.61% |
| 2020-12-31 | -341.73% |
| 2020-09-30 | -186.67% |
| 2020-06-30 | -125.28% |
| 2020-03-31 | -989.78% |
| 2019-12-31 | -130.83% |
| 2019-09-30 | -328.62% |
| 2019-06-30 | -200.65% |
| 2019-03-31 | -160.68% |
| 2018-12-31 | -179.84% |
| 2018-09-30 | -879.83% |
| 2018-06-30 | -207.75% |
| 2018-03-31 | -202.06% |
| 2017-12-31 | -96.06% |
| 2017-09-30 | 24.55% |
| 2017-06-30 | 5.15% |
| 2017-03-31 | -128.76% |
| 2016-12-31 | 59.49% |
| 2016-09-30 | -60.40% |
| 2016-06-30 | -45.48% |
| 2016-03-31 | -83.62% |
| 2015-12-31 | -55.96% |
| 2015-09-30 | 178.95% |
| 2015-06-30 | 73.72% |
| 2015-03-31 | -21.26% |
| 2014-12-31 | -386.95% |
| 2014-09-30 | -722.46% |
| 2014-06-30 | -594.99% |
| 2014-01-31 | -56887.50% |
| 2013-10-31 | -729.09% |
| 2013-07-31 | -3783.37% |
| 2013-04-30 | -509.64% |
| 2013-01-31 | -1192.60% |
| 2012-10-31 | -1770.85% |
| 2012-04-30 | -656.30% |
| 2012-01-31 | -758.14% |
| 2011-10-31 | -193.10% |
| 2011-07-31 | -30.23% |
| 2011-04-30 | -625.35% |
| 2011-01-31 | -891.78% |
| 2010-10-31 | -232.56% |
| 2010-07-31 | -25.14% |
